Cara Therapeutics, Inc.
One Parrott Drive
Shelton
Connecticut
06484
United States
Tel: 203-567-1500
Fax: 203-567-1510
Website: http://www.caratherapeutics.com/
Email: info@caratherapeutics.com
About Cara Therapeutics, Inc.
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated activity in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain and pruritus. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in both pain intensity and opioid-related side effects. In more than 440 subjects dosed to date, I.V. CR845 was observed to be well tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists. Cara recently initiated its Phase 3 program with I.V. CR845 in postoperative pain. Cara also has an ongoing Phase 2 trial of an oral tablet formulation of CR845, for the treatment of osteoarthritis (OA).
157 articles with Cara Therapeutics, Inc.
-
Cara Therapeutics to Present at Multiple Upcoming Investor Conferences
11/11/2020
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in the following upcoming virtual investor conferences and events in November and December: Stifel 2020 V
-
Cara Therapeutics Reports Third Quarter 2020 Financial Results
11/9/2020
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced financial results and operational highlights for the third quarter ended September 30, 2020.
-
Cara Therapeutics to Announce Third Quarter 2020 Financial Results on November 9, 2020
11/2/2020
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, November 9, 2020, at 4:30 p.m. ET to report third quarter 2020 financial results and provide a corporate update.
-
SWK Holdings' Subsidiary, Enteris BioPharma, Receives Milestone Payment from Cara Therapeutics
10/27/2020
First of multiple anticipated milestone payments related to the development of Oral KORSUVA™
-
Cara Therapeutics Announces Presentation at American Society of Nephrology Kidney Week 2020
10/21/2020
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that results from its KALM-2 pivotal Phase 3 trial of KORSUVA
-
Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus
10/20/2020
Vifor Pharma and Cara Therapeutics, Inc. announced that both companies have signed a license agreement for commercialization of Korsuva Injection for the treatment of chronic kidney disease-associated pruritus in the US dialysis market for non-Fresenius Medical Care clinics under a Cara 60%, Vifor Pharma 40% profit-sharing arrangement.
-
Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva™* to treat dialysis patients with pruritus
10/20/2020
Vifor Pharma and Cara Therapeutics, Inc. announced that both companies have signed a license agreement for commercialization of Korsuva Injection for the treatment of chronic kidney disease-associated pruritus in the US dialysis market for non-Fresenius Medical Care clinics under a Cara 60%, Vifor Pharma 40% profit-sharing arrangement.
-
Under terms of the deal, Connecticut-based Cara Therapeutics will receive $100 million in an upfront payment, as well as an equity investment of $50 million. Additional milestone payments could bring the total of the deal to about $290 million.
-
Cara Therapeutics Appoints Thomas Reilly as Chief Financial Officer
10/1/2020
Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, announced the appointment of Thomas Reilly as Chief Financial Officer, effective October 1, 2020.
-
Cara Therapeutics Reports Second Quarter 2020 Financial Results
8/10/2020
Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, announced financial results and operational highlights for the second quarter ended June 30, 2020.
-
Cara Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference
8/6/2020
Cara Therapeutics, Inc. announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 8:00 a.m. ET.
-
Cara Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020
8/3/2020
Cara Therapeutics, Inc. announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020, at 4:30 p.m. ET to report second quarter 2020 financial results and provide a corporate update.
-
Cara Therapeutics Expands Board of Directors with Appointment of Susan Shiff, Ph.D., M.B.A.
6/30/2020
Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, announced the appointment of Susan Shiff, Ph.D., M.B.A., to its Board of Directors.
-
Cara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
6/17/2020
Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, announced the completion of a planned sample size re-estimation of its KARE Phase 2 dose-ranging trial of Oral KORSUVA for the treatment of moderate-to-severe pruritus in atopic dermatitis patients.
-
Cara Therapeutics to Present at the Jefferies Virtual Healthcare Conference
5/27/2020
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer,
-
Cara Therapeutics Reports First Quarter 2020 Financial ResultsConference call today at 4:30 p.m. ET
5/11/2020
Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, announced financial results and operational highlights for the first quarter ended March 31, 2020.
-
Cara Therapeutics to Present at the Virtual BofA Securities 2020 Health Care Conference
5/7/2020
Cara Therapeutics, Inc. announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, and Joana Goncalves, M.D., Chief Medical Officer, will participate in a fireside chat at the virtual BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 9:00 a.m. ET.
-
Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020
5/4/2020
Cara Therapeutics, Inc. announced that the Company will host a conference call and live audio webcast on Monday, May 11, 2020, at 4:30 p.m. ET to report first quarter 2020 financial results and provide a corporate update.
-
Clinical Catch-Up: April 20-24
4/27/2020
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look. -
VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA™ injection in haemodialysis patients with Pruritus
4/21/2020
Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.02)